Healthcare and Life-Sciences Cases: The Primer Candidates Skip

Healthcare is a sector many candidates quietly hope not to draw. The vocabulary is dense, the system has more parties than a typical industry, and there is a lingering fear that the interviewer will ask something clinical. In most practice cases they don't. What they ask for is the same structured reasoning you use everywhere else, applied to an economy with an unusual shape.

That shape is the reason to spend a few hours on it. Our three-hour method for getting deep on an industry explains how to study a sector; this post is the map for one of them. You will get the players, how money moves between them, what makes drug and hospital economics different, the case types that come up, a glossary you can say out loud, and a patient-funnel calculation worked end to end.

One scope note. The system described here is the US-style one, with a mix of private and public payers, because many practice cases assume it. Systems differ sharply across countries; a single national payer, for example, changes pricing and access substantially. If the prompt does not say, asking which health system the client operates in is a perfectly good first clarifying question.

Start with the map: who pays whom

In most industries the customer uses the product and pays for it. Healthcare usually splits that into three roles:

• The patient uses the product but often pays only a share of the cost, through a co-payment or deductible.
• The clinician (physician, nurse practitioner, pharmacist) decides what is prescribed or performed.
• The payer (a private insurer, an employer plan or a government program) funds most of the cost and sets the rules on what it will cover.

Everyone else supplies, supports or sits between them:

• Providers deliver care: hospitals, physician groups, clinics, labs. They are paid by payers and patients, per service, per episode or per patient depending on the contract.
• Biopharma companies discover, develop and sell medicines. Payers decide whether those medicines are covered.
• Medtech companies make devices and diagnostics, sold mostly to providers.
• Intermediaries and service firms include wholesalers, pharmacy benefit managers that administer drug coverage, and contract research organizations that run trials for biopharma.

Drug economics in plain words

Three ideas explain most of what a pharma case is about.

Development is long, expensive and mostly fails. A medicine moves from the lab through clinical trials in three broad phases: safety in a small group, early evidence of effect and dose, then large confirmatory trials, often against placebo or the current standard of care. A regulator then decides on approval. Only a minority of candidates that enter human trials ever reach patients, and the cost of the failures is carried by the successes. That is why a drug asset is valued on a risk-adjusted basis: expected cash flows weighted by the probability of reaching the market.

Exclusivity is a clock. Patents and regulatory protections give the originator a period in which no one else can sell the same molecule. When that ends, generics can enter. A generic has the same active ingredient as a small-molecule drug; a biosimilar is a highly similar, but not identical, version of a biologic (a large molecule made in living cells). Price and volume for a branded small-molecule product commonly fall steeply after generic entry; biosimilar erosion is usually slower and varies more. Any forecast for a branded drug should say how many years of exclusivity remain.

Payers often hold the leverage, especially where several drugs treat the same condition. Approval is not the same as patients. Payers decide whether a drug is on their formulary, in which tier, and whether a prescriber must get prior authorization first. In return for favorable coverage, manufacturers often pay rebates, so the price on the list is not what the company collects. The gap is called gross-to-net, and a careful candidate sizes revenue on the net.

The cost structure follows. For many medicines, making each unit is cheap relative to its price, but research is heavy and so is the commercial machine. The economics are dominated by what is spent before launch and how long a premium can be charged after it.

Providers and payers: where the cost dynamics sit

A hospital is a high-fixed-cost business: buildings, equipment and, above all, staff. Labor is typically its largest cost line. Like an airline, its economics turn on utilization: beds filled, operating rooms used, scanners booked. Revenue is volume times reimbursement per case, and reimbursement depends on who the payer is, because different payers pay different rates for the same procedure. That is why payer mix appears in so many provider cases.

How a provider is paid matters too. Fee-for-service pays per item and rewards volume. Bundled and value-based arrangements pay a set amount per episode, or tie payment to outcomes and total cost, which rewards efficiency and prevention. A margin case often hinges on which model applies.

A payer collects premiums and pays claims. Its headline ratio is the medical loss ratio: claims divided by premiums. If a plan collects $100 of premium and pays $85 of claims, the ratio is 85% and 15% is left for administration and profit. Notice the tension built into the system: one party's claims cost is another party's revenue, so many initiatives have a counterparty with the opposite incentive.

Four case types you will meet

• Launch and pricing. A company is about to launch a drug: how big is the opportunity and what should it charge? Branches: the patient funnel, the standard of care and competing treatments, value to payers, net price, and the speed of uptake. The questions in our pricing post apply here too.
• Market access. The drug is approved but prescriptions are low. Structure by who must say yes: the payer (coverage, tier, authorization), the clinician (awareness, evidence, habit) and the patient (cost, side effects, adherence). Find which gate is closed before proposing fixes.
• Provider operations. A hospital's margin is falling or waits are too long. Volume, reimbursement and cost per case, with utilization as the usual lever. The profitability logic in our full walkthrough transfers almost unchanged.
• Biotech or pipeline acquisition. Should the client buy a small company with one drug in late-stage trials? Risk-adjusted peak sales, years of exclusivity, competitors, and what the buyer can add. The four-lever M&A framework gives you the outer shell.

A glossary you can say out loud

You do not need to recite these. You need to be able to use each one in a sentence without hesitating.

Worked example: the patient funnel

The prompt: a pharmaceutical client is preparing to launch a once-daily pill for a chronic condition. How large could annual revenue be at peak? Every number below is invented for the example and describes no real condition. The method is the one in our market-sizing post, specialized to patients. Each step is a share of the one before it.

Out loud, in millions: "Three hundred million people, 2% have it, that is 6 million. 60% diagnosed is 3.6 million. Half are treated, 1.8 million. 40% are eligible for us, 720 thousand. A quarter share is 180 thousand patients." As a cross-check, the whole chain collapses to one multiplication: 300,000,000 × 0.02 × 0.60 × 0.50 × 0.40 × 0.25 = 180,000.

Now turn patients into revenue. Assume patients take the drug 80% of the year on average, so 180,000 patients become 144,000 patient-years (180,000 × 0.80). Assume a list price of $12,500 per patient-year with rebates and discounts averaging 20% (real gaps vary widely by drug and class; this is illustrative), so net price is $10,000 ($12,500 × 0.80). Peak annual revenue is 144,000 × $10,000 = $1,440,000,000, or about $1.4 billion.

Because the steps multiply, a change in any one moves the answer by the same proportion. If the diagnosed rate were 70% instead of 60%, patients would rise to 210,000 and revenue to $1.68 billion, up 16.7%. If peak share were 20% instead of 25%, revenue would fall to $1.152 billion, down 20%. Say which assumption you trust least and how you would check it. Diagnosis rate can be moved by awareness and screening; share depends on competitors and payer access.

Finish by naming what the number leaves out. It is a peak-year figure. It ignores the ramp-up years before peak and the loss of exclusivity that eventually ends it. That is often where the interviewer's next question goes.

Where candidates go wrong

• Sizing on list price. Revenue is built on net price. Name the gap and assume a reasonable one.
• Treating the patient as the only customer. The payer and the prescriber can each block adoption. Ignore them and your market-size number is a ceiling, not a forecast.
• Forgetting the clock. Exclusivity and time to peak shape every revenue figure. A flat annual number hides both.
• Leaving patients out of the recommendation. A plan that raises profit by pricing patients out of treatment, or by cutting safety, is unfinished. Interviewers commonly follow up on access and outcomes, and one sentence acknowledging them reads as judgment.
• Hiding behind jargon. Use a term only if you can define it in plain words when asked.

How to use your three hours

Spend one hour on the map and glossary above, one on the economics of a single sub-sector (pharma is the usual choice), and one saying a patient funnel aloud with different numbers. Then run one case from each of the four types. Our market entry post is a useful companion for the launch-style cases, since both turn on right to win and not only on market size.